Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Nature Medicine 2026 Open access

Read full text
Authors: Lotte L Hoeijmakers, Petros Dimitriadis, S C M A Wijnen, Irene L. M. Reijers, Marta Lopez-Yurda, Alexander M. Menzies, Annegien Broeks, Sten Cornelissen, Alejandro Torres Acosta, A. van der Wal, R. Saw, Judith M. Versluis
+31 more Winan J. van Houdt, M. Wouters, Jurriaan Romano, E Rozeman, Lindsay G. Grijpink-Ongering, Ellen Kapiteijn, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Hanna Eriksson, G. Hospers, Jos A. van der Hage, Dirk J. Grünhagen, A. Witkamp, Judith M. Lijnsvelt, W. Martin C. Klop, Charlotte L. Zuur, A. Bruining, Abrahim Al-Mamgani, Thomas E. Pennington, Kerwin F. Shannon, Sydney Ch'ng, Andrew J. Colebatch, Maria Gonzalez, Andrew J. Spillane, John B A G Haanen, Robert V. Rawson, Richard A. Scolyer, Bart A. van de Wiel, A. van Akkooi, Georgina V. Long, Christian U. Blank
DOI: 10.1038/s41591-025-04158-9
Cited by: 6
References: 41

Fields of Study & Subjects

Cutaneous Melanoma Detection and Management Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Nature Medicine
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
3
Pages
952–963
Publication date
28 January 2026
Language
EN